Corona Remedies Stock: price and insider trades · India
3 insiders bought €7,544 of shares over the last 90 days, the latest by Kirtisinh Manoharsinh Parmar, filed 19 Aug 2026.
Corona Remedies: what insiders have been doing
Corona Remedies is a listed company. Filings by its managers are published through SEBI (PIT + SAST). In the past year (10 November 2025 to 10 November 2026), 12 filings came from 5 insiders.
The record shows 11 purchases on the open market worth €7,544, made by 4 insiders, against 1 sale by 1 insider. The totals do not cover 2 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The largest single trade was a purchase of €1,718 by Ranjanben Kirtisinh Parmar, published on 19 August 2026, equal to 0.0001% of the market capitalisation.
In the case of 10 purchases, another manager of the company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The latest purchase dates back some time: it was published 83 days ago, on 19 August 2026. Publication is fast: at least half of the trades appear on SEBI (PIT + SAST) on the same day. That lag is the time during which only the insider knows about the trade.
For context, the typical company on the same exchange (median of 1,984 companies) published 4 filings over the same period, against 12 filings here. Over the whole record (from 2026), the tally stands at 11 purchases and 1 sale.
Source: insider filings from SEBI (PIT + SAST). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- +2.3%Entry ₹2,138.75 · Close at T+30 ₹2,187.96
- +2.3%Entry ₹2,138.75 · Close at T+30 ₹2,187.96
- +2.3%Entry ₹2,138.75 · Close at T+30 ₹2,187.96
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Corona Remedies Strong Buy (bullish), based on 3 analysts. Average price target: ₹2,304.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
- 6 shares@ ₹2,082.300.0000% mcap3.2% of flowEquityMarket PurchaseSEBI:b541773b236dd8dd66624d7fb35dfa34d71813b8Canonical exit: 17 Nov 2026 (T+90)
- 50 shares@ ₹2,064.500.0001% mcap100.0% of flowEquityMarket PurchaseSEBI:36991b40d11be25b54213ec1103c2cd9ea992ecfCanonical exit: 17 Nov 2026 (T+90)
- 50 shares@ ₹2,122.500.0001% mcap27.4% of flowEquityMarket PurchaseSEBI:3f4b1eb3473a9eca91f2814aebf934039bd2871dCanonical exit: 17 Nov 2026 (T+90)
- 1 shares@ ₹2,082.000.0000% mcap0.5% of flowEquityMarket PurchaseSEBI:457e24c66286e1def7b1c5ebfc448e5eb3fbbe5dCanonical exit: 17 Nov 2026 (T+90)
- 2 shares@ ₹2,072.500.0000% mcap1.1% of flowEquityMarket PurchaseSEBI:3443e2227d45acac7c4472b39c5cfe1de1356465Canonical exit: 17 Nov 2026 (T+90)
- 48 shares@ ₹2,072.300.0001% mcap25.7% of flowEquityMarket PurchaseSEBI:a664512d103bc1f68d9f427ed2f17f6121549eb0Canonical exit: 17 Nov 2026 (T+90)
- 43 shares@ ₹2,082.400.0001% mcap23.1% of flowEquityMarket PurchaseSEBI:bc426bd4a360bed41402b11b5b8b60bf24899ca1Canonical exit: 17 Nov 2026 (T+90)
- 75 shares@ ₹2,089.700.0001% mcap45.1% of flowEquityMarket PurchaseSEBI:faba5218e01f9ced0cb88ae6f2ccd8b06c8b4fd8Canonical exit: 17 Nov 2026 (T+90)
- 90 shares@ ₹2,119.900.0001% mcap54.9% of flowEquityMarket PurchaseSEBI:9070a18a71e95b10bc42d41c1c30bfe944635c2fCanonical exit: 17 Nov 2026 (T+90)
- 35 shares@ ₹2,097.500.0001% mcap19.0% of flowEquityMarket PurchaseSEBI:5235267b4982b04a0dec2e82f0666ff3b13d8788Canonical exit: 17 Nov 2026 (T+90)
- 289,017 shares-MarketSEBI:19d95902959ecbe720830861fb94838b37b4c1b6Canonical exit: 15 Oct 2026 (T+90)
- 4,580,891 shares-MarketSEBI:864048fefd60059bc1b338d947391fe1360b3b1d
12 of 12 declarations
About Corona Remedies
Corona Remedies is a company operating in the XBOM market, specializing in the manufacture of pharmaceutical products. It focuses on developing innovative health solutions.